Conatus Pharmaceuticals Inc. (CNAT)

[staccani]

NASH prevalence in US:
http://www.uptodate.com/contents/epidemiology-clinical-features-and-diagnosis-of-nonalcoholic-fatty-liver-disease-in-adults

3-5% of general population

NASH Cirrhosis prevalence in the US

From CNAT 10K: 'NASH is one of the leading causes of cirrhosis in adults in the United States, and up to 25% of adults with NASH may have cirrhosis. Furthermore, NASH is expected to be the leading cause of liver transplant in the next five to ten years. There are currently no approved drugs for the treatment of NASH cirrhosis'.

So out of 324M people in US , 4% x 25% x 324M = 3.2M people ca are estimated to have NASH Cirrhosis in the US